The pressure's on Novo's marketing force as FDA nod for liraglutide nears

Novo Nordisk ($NVO) may be nearing the regulatory finish line with an obesity-fighting dose of liraglutide, up for debate by the FDA's advisers this week. But as its struggling rivals can attest, when it comes to weight-loss drugs, approval isn't everything, and it'll be up to Novo's marketing machine to take it from there. More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.